Skip to main content

Novavax signs multibillion-dollar deal with Sanofi to commercialize Covid vaccine, develop combination shots

The deal will allow Novavax to lift its "going concern" warning, which it first issued in 2023 due to having "substantial doubt" about its ability to survive.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.